TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06095908

Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacain administered with two different ways to the patients, postoperative pain recorded

Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacain administered with two different ways to the patients, postoperative pain recorded
Study: NCT05366166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (intensity modulated radiation therapy)
Description: In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
Study: NCT06402019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)
Description: Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group went under multiple sessions of normal saline injection.
Study: NCT05791617

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac PET/MRI
Description: Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac PET/MRI
Description: Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: NT-proBNP
Description: NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: NT-proBNP
Description: NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Study: NCT05939687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesh
Description: We'll use mesh repair for prevention of stoma-site hernias in the study group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-mesh
Description: We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
Study: NCT05899530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: Expansion using Invisalign versus conventional expander

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional expander
Description: conventional expander
Study: NCT05686577

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05444816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised Neurofeedback training at home
Description: The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed.
Study: NCT05423951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Description: For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
Study: NCT05595135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive interactive text messaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive medication reminders via smart pill bottle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05070585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isothiocyanate rich sprouts
Description: Isothiocyanate rich sprout juice consumption for 1 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Sprout juice devoid of isothiocyanates for 1 week
Study: NCT05138354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: 1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: 1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles.
Study: NCT04771910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical cream with live probiotic bacteria
Description: Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
Study: NCT04074811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.
Study: NCT05227248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Patients were administered 20 grams of dark chocolate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Chocolate
Description: Patients were administered 7.5 grams of milk chocolate
Study: NCT06115174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\].

Intervention type: RADIATION
Group type: OTHER
Intervention: FOLFOX
Description: (leucovorin, fluorouracil, oxaliplatin)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: (leucovorin, fluorouracil, oxaliplatin)

Intervention type: RADIATION
Group type: OTHER
Intervention: XELOX
Description: (oxaliplatin + capecitabine)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: (oxaliplatin + capecitabine)

Intervention type: DRUG
Group type: OTHER
Intervention: Monoclonal antibodies (target therapy)
Description: target therapy (Bevacizumab).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monoclonal antibodies (target therapy)
Description: target therapy (Bevacizumab).
Study: NCT05474339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Using Cardiac rehabilitation for patients after coronary artery bypass graft
Study: NCT06415539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physical therapy program
Description: Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical physical therapy program
Description: Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Children in this group will be given vestibular and proprioceptive exercise training in addition to the classical physiotherapy program. Skateboard, swing, hammock, bowl, ball, sensory pads, ball pool, slide, climbing bar, trampoline and balance board will be used as materials in vestibular and proprioceptive exercise training. In addition, at the end of the training sessions, parents will be informed about the application of exercise training to daily activities.
Study: NCT04571840

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multiparametric MRI +/- prostate biopsy
Description: MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biparametric MRI +/- prostate biopsy
Description: MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
Study: NCT05159791

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive coronary blood flow assessment and simulations and fluid dynamic patient specific simulation
Description: The coronary blood flow and its distribution between the anomalous and normal artery will be measured by invasive coronary catheterization. Coronary artery flow will be calculated based on intravascular ultrasound (IVUS) and pressure difference measurements. After the IVUS assessment, a pressure transducer (FFR/iFR probe) will be inserted in the coronary artery for pressure measurements. The measurements will be done in the anomalous and normal coronary arteries in each patient to determine coronary flow distribution. Patient's specific heart parameters will be retrieve from CT, MRI and other diagnostic tests and integrated in the simulation module.
Study: NCT06139848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior-anterior spinal mobilization, prone press up Techniques
Description: Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior-anterior spinal mobilization, prone press up Techniques
Description: Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions.
Study: NCT04844320

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cobb angle measurements
Description: PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cobb angle measurements
Description: PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cobb angle measurements
Description: PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
Study: NCT06017245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole-body vibration to Control
Description: Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration to Control
Description: Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration to Control
Description: Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
Study: NCT04850651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib；Fluconazole
Description: Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18.
Study: NCT06188117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Digital Game Addiction Awareness Training'
Description: Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'.